Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cybin, Fibrogen, Jazz, OS Therapies, Valneva.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Absci, Almirall, Coherus, Cormedix, Intas, Keros, Melinta, Novo Nordisk, Prothena.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Assembly, Braintree, Eledon, Eli Lilly, OS, Palisade, Sellas, Spinogenix.
Biopharma companies raised $34.89 billion through financings in the first seven months of 2025, including $5.66 billion in July, down from $7.38 billion in June.This year’s total falls short of $74.03 billion in the first seven months of 2024 and more than $80 billion in 2020 and 2021. However, 2025 is on track to outperform post-pandemic lows of 2022 and 2023, when the seven-month totals reached $33.14 billion and $36.47 billion, respectively.
Drug companies and organizations challenging the Medicare drug negotiations have yet to convince a U.S. court that the process, mandated by the 2022 Inflation Reduction Act, violates the Constitution. The most recent decisions came this week when the U.S. Court of Appeals for the Second Circuit ruled Aug. 7 against Boehringer Ingelheim GmbH and the Sixth Circuit ruled Aug. 6 against a challenge filed by the Dayton, Ohio, Chamber of Commerce, the U.S. Chamber, and the Ohio and Michigan Chambers.
RSS
